Contineum Therapeutics (CTNM) Other financing activities (2023 - 2026)

Contineum Therapeutics' Other financing activities history runs 4 years deep, the most recent figure standing at $582000.0 for Q2 2026.

• In Q2 2026, Other financing activities rose 139.51% year-over-year to $582000.0; the TTM figure through Jun 2026 stood at $980000.0 (up 82.5% YoY), while the FY2025 annual figure was $467000.0, up 15.31% from the prior year.
• Other financing activities for Q2 2026 stood at $582000.0, up from $198000.0 in the prior quarter.
• The five-year high for Other financing activities was $582000.0 in Q2 2026, with the low at $8000.0 in Q1 2023.
• The 4-year median for Other financing activities is $82000.0 (2023), against an average of $139307.7.
• The sharpest annual moves came in 2024 and 2025: Other financing activities plunged 84.15% in 2024, then soared 1769.23% in 2025.
• Contineum Therapeutics' Other financing activities stood at $50000.0 in 2023, then jumped by 414.0% to $257000.0 in 2024, then retreated by 22.18% to $200000.0 in 2025, then surged by 191.0% to $582000.0 in 2026.
• Business Quant data shows CTNM's Other financing activities at $582000.0 in Q2 2026, $198000.0 in Q1 2026, and $200000.0 in Q4 2025.